PATENT CLAIM ANALYSIS

Application Number: 15926015
Application Type: Utility
Filing Date: 2018-03
Publication Date: 2018-07
Patent Classification: ["514", "279000"]

Abstract:
This invention relates to novel substituted benzamide according to Formula (I) which are inhibitors of Enhancer of Zeste Homolog 2 (EZH2), to pharmaceutical compositions containing them, to processes for their preparation, and to their use in therapy for the treatment of cancers.

Claim (Index 1):
A method of treating a hematologic cancer comprising administering to a patient with cancer a therapeutically effective amount of a compound of formula (I): wherein: R 1  is methyl; R 2  is methyl; R 3  is hydrogen; R 4  is methyl; R 5  is \u2014NR a R b ; R 6  is phenyl, wherein said phenyl is optionally substituted by \u2014(C 1 -C 6 )alkyl(R c ); R c  is \u2014NR a R b ; and R a  and R b  are each independently hydrogen, (C 1 -C 8 )alkyl, (C 2 -C 8 )alkenyl, (C 2 -C 8 )alkynyl, (C 3 -C 10 )cycloalkyl, (C 5 -C 8 )cycloalkenyl, heterocycloalkyl, or aryl, wherein said (C 1 -C 8 )alkyl, (C 2 -C 8 )alkenyl, (C 2 -C 8 )alkynyl, cycloalkyl, cycloalkenyl, heterocycloalkyl, or aryl group is optionally substituted by 1, 2 or 3 groups independently selected from the group consisting of halo, hydroxyl, (C 1 -C 4 )alkoxy, amino, (C 1 -C 4 )alkylamino, \u2014N((C 1 -C 4 )alkyl) 2 , \u2014CO 2 H, \u2014CO 2 (C 1 -C 4 )alkyl, \u2014CONH 2 , \u2014CONH(C 1 -C 4 )alkyl, \u2014CON((C 1 -C 4 )alkyl) 2 , \u2014SO 2 (C 1 -C 4 )alkyl, \u2014SO 2 NH 2 , \u2014SO 2 NH(C 1 -C 4 )alkyl, and \u2014SO 2 N((C 1 -C 4 )alkyl) 2 ; and wherein said heterocycloalkyl is selected from the group consisting of pyrrolidinyl, tetrahydrofuranyl, piperidinyl, piperazinyl, morpholinyl, thiomorpholinyl, and tetrahydropyranyl; or R a  and R b  taken together with the nitrogen to which they are attached represent a 5 or 6 membered saturated ring, optionally containing an additional heteroatom selected from oxygen, nitrogen, and sulfur, wherein said ring is optionally substituted by 1, 2 or 3 groups independently selected from the group consisting of (C 1 -C 4 )alkyl, (C 1 -C 4 )haloalkyl, amino, (C 1 -C 4 )alkylamino, ((C 1 -C 4 )alkyl)((C 1 -C 4 )alkyl)amino, hydroxyl, oxo, (C 1 -C 4 )alkoxy, and (C 1 -C 4 )alkoxy(C 1 -C 4 )alkyl; or a pharmaceutically acceptable salt thereof

Metadata:
- Claim Count in Document: 3.0
- Percentile: 90.0
- Lexical Diversity: 1.31579
- Patent Class: 514.0
- Transitional Phrase Type: open
- Component Type: 1
- Foreign Priority: False
- Related Applications: ['15379649', '14400896', '13696436', '14458305', '13990505']

Analysis Scores:
- 35 USC 101 Eligibility (BERT): 0.7533999295998101
- 35 USC 102 Novelty (BERT): 0.5157320934060065
- Combined Prediction Score: 0.7296331459804297
- Mean Citation Score: 313.60831
- Max Citation Score: 315.5898
- Similarity Product: 292.2841591959715

Labels:
- Claim Label 101: 1
- Claim Label 102: 1
- Claim Label 103: 1
- Claim Label 112: 0
- Combined Label: 1
- Label 101 Adjusted: 1

Dataset: test